This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Sage Therapeutics, Inc.. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Title: Innovations of Jean-Cosme Dodart
Introduction
Jean-Cosme Dodart is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of neuroactive steroids, focusing on their compositions and uses. With a total of 2 patents, Dodart's work is pivotal in advancing treatments for various CNS-related conditions in mammals.
Latest Patents
Dodart's latest patents include innovative compounds that are designed to be useful for the prevention and treatment of a variety of CNS-related conditions. The compounds are provided according to specific formulas and include pharmaceutically acceptable salts. These inventions are aimed at enhancing therapeutic options for patients suffering from neurological disorders.
Career Highlights
Jean-Cosme Dodart is currently associated with Sage Therapeutics, Inc., where he continues to develop groundbreaking solutions in the pharmaceutical field. His expertise in neuroactive steroids has positioned him as a key figure in the research and development of new treatments.
Collaborations
Dodart has collaborated with esteemed colleagues such as Ravindra B Upasani and Boyd Lynn Harrison. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Jean-Cosme Dodart's contributions to the field of neuroactive steroids and his ongoing work at Sage Therapeutics, Inc. highlight his commitment to advancing medical science. His patents reflect a dedication to improving the lives of those affected by CNS-related conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile